Virchows Archiv

, Volume 447, Issue 6, pp 947–953 | Cite as

Quantification of clonal hematopoiesis in polycythemia vera

  • Udo Siebolts
  • Murat Ates
  • Rüdiger Spitz
  • Jürgen Thiele
  • Claudia Wickenhauser
Original Article

Abstract

Polycythemia vera (PV) is believed to represent a clonal trilineage myeloaccumulative hematopoietic disorder. This study was undertaken to estimate for the first time the proportion not only of the neoplastic clone but also of clonal and residual nonneoplastic CD34+ progenitor cells. Chromosomal abnormalities, including trisomy 8 or 9, are phenomena associated in about 20% of PV patients. Therefore, we screened peripheral blood (PB) mononuclear cells of PV patients in the chronic phase of the disease and looked for chromosomal abnormalities performing comparative genomic hybridization. Two of the ten patients revealed cytogenetic changes, including trisomy 8 or 9. To quantify the proportion of cytogenetic abnormal cells in these patients, we applied fluorescence in situ hybridization (FISH) technique on immunomagnetically enriched cell fractions. Ninety percent of the mononuclear cells and up to 79% of PB-derived CD34+ progenitor cells presented three signals for chromosome 8 or 9. The diagnostic value of FISH to detect trisomies in trephine biopsies was then tested in all patients under study. Although the probability to detect FISH signals in a certain section plane is reduced, constantly 10–15% of the cells revealed three signals. Concerning the CD34+ progenitor cell pool, a distinct nonclonal population exists in these patients. Our data underline the stem cell character of PV and additionally quantify the proportion of clonal CD34+ progenitor cells for the first time. The finding of a distinct, not aberrant, CD34+ progenitor cell population in chronic phase PV may offer perspectives in treatment of the disease. Finally, FISH analysis of bone marrow biopsies can be helpful to consolidate diagnosis of early PV.

Keywords

Polycythemia vera Chromosomal aberrations CD34+ FISH CGH 

References

  1. 1.
    Amiel A, Gaber E, Manor Y, Fejgin M, Joseph-Lerner N, Ravid M, Lishner M (1995) Fluorescence in situ hybridization for the detection of trisomies 8 and 9 in polycythemia vera. Cancer Genet Cytogenet 79:153–156CrossRefPubMedGoogle Scholar
  2. 2.
    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061PubMedGoogle Scholar
  3. 3.
    Bench AJ, Nacheva EP, Champion KM, Green AR (1998) Molecular genetics and cytogenetics of myeloproliferative disorders. Bailliere's Clin Haematol 11:819–848CrossRefGoogle Scholar
  4. 4.
    Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM (1995) Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 85:3636–3645PubMedGoogle Scholar
  5. 5.
    Busson M, Romana S, Khac FN, Bernard O, Berger R (2004) Cryptic translocations involving chromosome 20 in polycythemia vera. Ann Genet 47:365–371PubMedGoogle Scholar
  6. 6.
    Carneskog J, Kutti J, Wadenvik H, Lundberg PA, Lindstedt G (1998) Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol 60:278–282PubMedCrossRefGoogle Scholar
  7. 7.
    Cashman J, Henkelman D, Humphries K, Eaves C, Eaves A (1983) Individual BFU-E in polycythemia vera produce both erythropoietin dependent and independent progeny. Blood 61:876–884PubMedGoogle Scholar
  8. 8.
    Champion KM, Gilbert JG, Asimakopoulos FA, Hinshelwood S, Green AR (1997) Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol 97:920–926CrossRefPubMedGoogle Scholar
  9. 9.
    Florensa L, Besses C, Zamora L, Bellosillo B, Espinet B, Serrano S, Woessner S, Sole F (2004) Endogenous erythroid and megakaryocytic circulating progenitors, HUMARA clonality assay, and PRV-1 expression are useful tools for diagnosis of polycythemia vera and essential thrombocythemia. Blood 103:2427–2428CrossRefPubMedGoogle Scholar
  10. 10.
    Gale RE, Fielding AK, Harrison CN, Linch DC (1997) Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br J Haematol 98:512–519CrossRefPubMedGoogle Scholar
  11. 11.
    Gilbert HL, Acharya J, Pearson TC (1998) Implications for the use of X-chromosome inactivation patterns and their relevance to the myeloproliferative disorders. Eur J Haematol 61:282–283PubMedGoogle Scholar
  12. 12.
    Goldman JM (2005) A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 352:1744–1746CrossRefPubMedGoogle Scholar
  13. 13.
    Herishanu Y, Lishner M, Bomstein Y, Kitay-Cohen Y, Fejgin MD, Gaber E, Amiel A (2001) Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients. Cancer Genet Cytogenet 128:154–157CrossRefPubMedGoogle Scholar
  14. 14.
    James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148CrossRefPubMedGoogle Scholar
  15. 15.
    Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood [Epub ahead of print]Google Scholar
  16. 16.
    Kaushansky K (2005) On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 105:4187–4190CrossRefPubMedGoogle Scholar
  17. 17.
    Knuutila S, Armengol G, Bjorkqvist AM, el-Rifai W, Larramendy ML, Monni O, Szymanska J (1998) Comparative genomic hybridization study on pooled DNAs from tumors of one clinical–pathological entity. Cancer Genet Cytogenet 100:25–30CrossRefPubMedGoogle Scholar
  18. 18.
    Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP, Skoda RC (2003) Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 102:1869–1871CrossRefPubMedGoogle Scholar
  19. 19.
    Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790CrossRefPubMedGoogle Scholar
  20. 20.
    Kralovics R, Stockton DW, Prchal JT (2003) Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 102:3793–3796CrossRefPubMedGoogle Scholar
  21. 21.
    Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397CrossRefPubMedGoogle Scholar
  22. 22.
    Lichter P, Joos S, Bentz M, Lampel S (2000) Comparative genomic hybridization: uses and limitations. Semin Hematol 37:348–357PubMedCrossRefGoogle Scholar
  23. 23.
    Messora C, Bensi L, Vecchi A, Longo R, Giacobbi F, Temperani P, Bevini M, Emilia G, Sacchi S (1994) Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol 86:402–404PubMedGoogle Scholar
  24. 24.
    Najfeld V, Montella L, Scalise A, Fruchtman S (2002) Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 119:558–566CrossRefPubMedGoogle Scholar
  25. 25.
    Pellagatti A, Vetrie D, Langford CF, Gama S, Eagleton H, Wainscoat JS, Boultwood J (2003) Gene expression profiling in polycythemia vera using cDNA microarray technology. Cancer Res 63:3940–3944PubMedGoogle Scholar
  26. 26.
    Spivak JL (2002) Polycythemia vera: myths, mechanisms, and management. Blood 100:4272–4290CrossRefPubMedGoogle Scholar
  27. 27.
    Temerinac S, Klippel S, Strunck E, Roder S, Lubbert M, Lange W, Azemar M, Meinhardt G, Schaefer HE, Pahl HL (2000) Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95:2569–2576PubMedGoogle Scholar
  28. 28.
    Westwood NB, Gruszka-Westwood AM, Atkinson S, Pearson TC (2001) Polycythemia vera: analysis of DNA from blood granulocytes using comparative genomic hybridization. Haematologica 86:464–469PubMedGoogle Scholar
  29. 29.
    Westwood NB, Gruszka-Westwood AM, Pearson CE, Delord CF, Green AR, Huntly BJ, Lakhani A, McMullin MF, Pearson TC (2000) The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridization. Br J Haematol 110:839–846CrossRefPubMedGoogle Scholar
  30. 30.
    Wickenhauser C, Perez F, Siebolts U, Lorenzen J, Varus E, Frimpong S, Thiele J (2003) Structural, antigenetic and transcriptional characteristics in peripheral blood CD34+ progenitor cells from polycythemia vera patients: evidence for delayed determination. Int J Oncol 23:437–443PubMedGoogle Scholar
  31. 31.
    Wickenhauser C, Thiele J, Perez F, Varus E, Stoffel MS, Kvasnicka HM, Beelen DW, Schaefer UW (2002) Mixed chimerism of the resident macrophage population after allogeneic bone marrow transplantation for chronic myeloid leukemia. Transplantation 73:104–111CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Udo Siebolts
    • 1
  • Murat Ates
    • 1
  • Rüdiger Spitz
    • 2
  • Jürgen Thiele
    • 1
  • Claudia Wickenhauser
    • 1
  1. 1.Institute of PathologyUniversity of CologneCologneGermany
  2. 2.Children's Hospital, Pediatric OncologyUniversity of CologneCologneGermany

Personalised recommendations